Navigation Links
Investigation of American Oriental Bioengineering, Inc. by Securities Lawyers at Goldfarb LLP Law Firm for Potential Shareholder Claim
Date:6/26/2012

DALLAS, June 26, 2012 /PRNewswire/ -- Goldfarb LLP is investigating whether the board of directors of American Oriental Bioengineering, Inc. (OTC: AOBI) violated shareholder protection laws as evidenced through alleged inconsistencies in the company's financial statements. Concerned AOBI investors who purchased stock before June 15, 2012 are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbllp.com about their rights and remedies.

"On March 16, 2012, auditor Ernst & Young informed the company's audit committee of discrepancies in the company's financial statements for fiscal year 2011. As a result, trading halted, the stock was delisted, and shares fell almost 60%," securities lawyer Hamilton Lindley said. "Our proposed shareholder lawsuit will seek to ensure that proper controls are placed to ensure accurate financial reporting, to correct any improper behavior, and to improve the company's value for investors."

Goldfarb LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. American Oriental Bioengineering, Inc. shareholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at hlindley@goldfarbllp.com or 877-583-2855.

Hamilton Lindley
Goldfarb LLP
2501 N. Harwood, Ste. 1801
Dallas, TX 75201
(877) 583-2855 Toll Free Telephone
(214) 583-2233 Local Phone Number
(214) 583-2234 Fax Number
hlindley@goldfarbllp.com 
www.goldfarbllp.com


'/>"/>
SOURCE Goldfarb LLP
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology news :

1. Child welfare investigation predicts mental health problems in young children
2. American College of Rheumatology releases first classification criteria for polymyalagia rheumatica
3. Common North American frog identified as carrier of deadly amphibian disease
4. UC research tests new tool to guide reintroduction of the American chestnut
5. American Society of Plant Biologists honors early career women scientists
6. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
7. Professor known for work with hunter-gatherers elected to American Academy of Arts and Sciences
8. Elsevier selected as new publisher of the American Journal of Geriatric Psychiatry
9. New study published on fertility awareness among American university students
10. The American Society for Microbiology honors Ellen Jo Baron
11. Steve Fisher joins American Health IT LLC as VP of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... Lugano, Switzerland, 14 September 2012 -- Ahead of the ... be released during the ESMO 2012 Congress, over 1,600 ... 2012 at 9:00 (CEST) to anticipate the flavor of ... emerging strategies set to combat cancer, signposting future directions ...
... have developed a method that for the first time ... proteins and subsequently remove them in a repeatable cycle., ... this week in the journal Nature Methods , ... naturally formed proteins in order to create better antibiotics, ...
... ,Boston (Sept. 14, 2012) Eye injuries in ... as weapons, tactics, technology and strategies have evolved. ... cause extensive damage areas not protected by body armor. ... Institute, Massachusetts Eye and Ear will convene in Boston, ...
Cached Biology News:Noteworthy studies at the ESMO 2012 Congress 2Noteworthy studies at the ESMO 2012 Congress 3Noteworthy studies at the ESMO 2012 Congress 4Noteworthy studies at the ESMO 2012 Congress 5Noteworthy studies at the ESMO 2012 Congress 6Noteworthy studies at the ESMO 2012 Congress 7Chemists develop reversible method of tagging proteins 2Chemists develop reversible method of tagging proteins 3
(Date:4/16/2015)... April 16, 2015 OncoTAb, ... Charlotte (UNC Charlotte) spin-out company, announced today the ... Ph.D., M.D., as Chief Operating Officer (COO). Cooper ... experience in developing clinical diagnostic and biotechnology platforms ... disease. , Cooper’s extensive career transcends the field ...
(Date:4/16/2015)... - Bioenterprise Corporation is pleased to announce that it will ... , PEI.  Bioenterprise has established a 3-year strategic ... the commercialization of agricultural technologies and innovations. ... They have been at the heart of agri-innovation in ... Dave Smardon , President & CEO of Bioenterprise Corporation.  ...
(Date:4/16/2015)... SAN DIEGO , April 16, 2015 ... company dedicated to improving cancer surgeries, announced today that ... lead fluorescent cancer illuminator, AVB-620, in women with primary, ... trial, the company also welcomed the addition of ... affairs. The open label, dose escalation study ...
(Date:4/16/2015)... BETHESDA, Md. , April 16, 2015 /PRNewswire/ ... Bio"), a biotechnology company developing non-toxic DCVax® personalized ... has been included in the Loncar Cancer Immunotherapy ... help investors better track the immunotherapy field within ... founders have selected "the top 25 companies" in ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2Bioenterprise Corporation Expands into the Maritimes 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3
... 5 Experts from PAREXEL International Corporation (Nasdaq: ... services provider, will address important industry issues at ... being held from March 23 - 25, 2009 ... leaders will present on topics ranging from global ...
... BEACH, California and AMSTERDAM, March 5 ,Agendia, a ... the,appointment of Dr. Albert A. (Al) Luderer to ... Dr. Luderer has more than 30 years of ... therapeutic development. Currently, he,is the Chief Executive Officer ...
... WALTHAM, Mass., March 5 Proteon Therapeutics, Inc., announced ... Series B equity financing, led by MPM Capital on ... L.P. This announcement follows the initiation of a ... PRT-201, in patients with end stage renal disease undergoing ...
Cached Biology Technology:PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 2PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 3PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 4PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 5Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board 2Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company 2
... depletion cocktail is tailored to ... from suspensions of non-human primate ... separated using the StemSep (or ... selection system, achieving a 2.6 ...
... is tailored to highly enrich ... of non-human primate (Rhesus monkey) ... the StemSep compatible 0.5 Tesla) ... CD4+ T cell content of ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
...
Biology Products: